simAbs is an acronym for Smart Integrated Manufacturing of Antibodies. simAbs was founded in 2019 and has developed an innovative platform that enables fast, flexible and cost-effective biologics development and manufacturing for biopharmaceutical companies. We have an extensive track record and a thorough knowledge of continuous bioprocessing. Our strong partnerships with universities and industry partners have given us opportunities to test and continuously improve our system. We believe that continuous production of biologics will be the technology of the future as it is being strongly supported by regulatory agencies. It shows also many advantages like consistent product quality, a decrease in cost of goods and more reliability in terms of time to market.  Read more.